UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No. )*

 

Tango Therapeutics, Inc.

(Name of Issuer)

 

Common stock, $0.001 par value per share

(Title of Class of Securities)

 

87583X109

(CUSIP Number)

 

August 11, 2023

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨         Rule 13d-1(b)

 

x        Rule 13d-1(c)

 

¨         Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

CUSIP No.   87583X109
1.

Names of Reporting Persons

Nextech Crossover I SCSp

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)  ¨      (b) x (1) 

3. SEC Use Only
4.

Citizenship or Place of Organization

Luxembourg

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

 5.

Sole Voting Power

5,533,980 shares

6.

Shared Voting Power

0

7.

Sole Dispositive Power

5,533,980 shares

8.

Shared Dispositive Power

0

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

5,533,980 shares

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
11.

Percent of Class Represented by Amount in Row (9)

5.4% (2)

12.

Type of Reporting Person (See Instructions)

PN

       

(1)This Schedule 13G is filed by Nextech Crossover I SCSP (“Nextech Crossover LP”), Nextech Crossover I GP S.à r.l. (“Nextech Crossover GP”), Ian Charoub, (“Charoub”), Costas Constantinides (“Constantinides”) and Rocco Sgobbo (“Sgobbo” and, with Nextech Crossover LP, Nextech Crossover GP, Charoub and Constantinides, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)The percent of class was calculated based on the sum of (i) 88,467,269 shares of Common Stock outstanding as of August 2, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2023, and (ii) 13,196,671 shares of Common Stock issued in the private placement of equity securities by the Issuer that closed on August 11, 2023.

 

2

 

 

CUSIP No.   87583X109
1.

Names of Reporting Persons

Nextech Crossover I GP S.à r.l.

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ¨        (b) x (1) 

3. SEC Use Only
4.

Citizenship or Place of Organization

Luxembourg

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

 5.

Sole Voting Power

5,533,980 shares

6.

Shared Voting Power

0

7.

Sole Dispositive Power

5,533,980 shares

8.

Shared Dispositive Power

0

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

5,533,980 shares

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
11.

Percent of Class Represented by Amount in Row (9)

5.4% (2)

12.

Type of Reporting Person (See Instructions)

OO

       

(1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)The percent of class was calculated based on the sum of (i) 88,467,269 shares of Common Stock outstanding as of August 2, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2023, and (ii) 13,196,671 shares of Common Stock issued in the private placement of equity securities by the Issuer that closed on August 11, 2023.

 

3

 

 

CUSIP No.   87583X109
1.

Names of Reporting Persons

Ian Charoub

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ¨         (b) x (1) 

3. SEC Use Only
4.

Citizenship or Place of Organization

Sweden

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

 5.

Sole Voting Power

0

6.

Shared Voting Power

5,533,980 shares

7.

Sole Dispositive Power

0

8.

Shared Dispositive Power

5,533,980 shares

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

5,533,980 shares

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
11.

Percent of Class Represented by Amount in Row (9)

5.4% (2)

12.

Type of Reporting Person (See Instructions)

IN

       

(1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)The percent of class was calculated based on the sum of (i) 88,467,269 shares of Common Stock outstanding as of August 2, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2023, and (ii) 13,196,671 shares of Common Stock issued in the private placement of equity securities by the Issuer that closed on August 11, 2023.

 

4

 

 

CUSIP No.   87583X109
1.

Names of Reporting Persons

Costas Constantinides

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ¨        (b) x (1) 

3. SEC Use Only
4.

Citizenship or Place of Organization

Cyprus

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

 5.

Sole Voting Power

0

6.

Shared Voting Power

5,533,980 shares

7.

Sole Dispositive Power

0

8.

Shared Dispositive Power

5,533,980 shares

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

5,533,980 shares

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
11.

Percent of Class Represented by Amount in Row (9)

5.4% (2)

12.

Type of Reporting Person (See Instructions)

IN

       

(1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)The percent of class was calculated based on the sum of (i) 88,467,269 shares of Common Stock outstanding as of August 2, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2023, and (ii) 13,196,671 shares of Common Stock issued in the private placement of equity securities by the Issuer that closed on August 11, 2023.

 

5

 

 

CUSIP No.   87583X109
1.

Names of Reporting Persons

Rocco Sgobbo

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ¨        (b) x (1) 

3. SEC Use Only
4.

Citizenship or Place of Organization

Switzerland

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

 5.

Sole Voting Power

0

6.

Shared Voting Power

5,533,980 shares

7.

Sole Dispositive Power

0

8.

Shared Dispositive Power

5,533,980 shares

9.

Aggregate Amount Beneficially Owned by Each Reporting Person

5,533,980 shares

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
11.

Percent of Class Represented by Amount in Row (9)

5.4% (2)

12.

Type of Reporting Person (See Instructions)

IN

       

(1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)The percent of class was calculated based on the sum of (i) 88,467,269 shares of Common Stock outstanding as of August 2, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2023, and (ii) 13,196,671 shares of Common Stock issued in the private placement of equity securities by the Issuer that closed on August 11, 2023.

 

6

 

 

Item 1.
 
  (a)

Name of Issuer

 

Tango Therapeutics, Inc.

  (b)

Address of Issuer’s Principal Executive Offices

 

201 Brookline Ave., Suite 901

Boston, MA 02215

 
Item 2.
 
  (a)

Name of Person Filing

 

Nextech Crossover I SCSp (“Nextech Crossover LP”)

Nextech Crossover I GP S.à r.l. (“Nextech Crossover GP”)

Ian Charoub (“Charoub”)

Costas Constantinides (“Constantinides”)

Rocco Sgobbo (“Sgobbo”)

 

  (b)

Address of Principal Business Office or, if none, Residence

 

8 rue Lou Hemmer

L-1748 Luxembourg-Findel

Grand-Duché de Luxembourg

 

  (c) Citizenship    
         
    Name Citizenship or Place of Organization  
    Nextech Crossover LP Luxembourg  
    Nextech Crossover GP Luxembourg  
    Charoub Sweden  
    Constantinides Cyprus  
    Sgobbo Switzerland  

 

  (d)

Title of Class of Securities

 

Common Stock, $0.001 par value (“Common Stock”)

  (e)

CUSIP Number

 

87583X109

 

 

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
   
  Not applicable

 

7

 

 

 
Item 4. Ownership
   
The following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1 is provided as of August 21, 2023:

 

Reporting Persons 

Shares
Held
Directly

 

Sole
Voting
Power

 

Shared

Voting

Power

 

Sole

Dispositive

Power

 

Shared

Dispositive

Power

 

Beneficial

Ownership

 

Percentage

of Class (2)

 
Nextech Crossover LP (1)  5,533,980  5,533,980  0  5,533,980  0  5,533,980  5.4%
Nextech Crossover GP (1)  0  5,533,980  0  5,533,980  0  5,533,980  5.4%
Charoub (1)  0  0  5,533,980  0  5,533,980  5,533,980  5.4%
Constantinides (1)  0  0  5,533,980  0  5,533,980  5,533,980  5.4%
Sgobbo (1)  0  0  5,533,980  0  5,533,980  5,533,980  5.4%

 

(1)     The shares are held by Nextech Crossover LP. Nextech Crossover GP serves as the sole general partner of Nextech Crossover LP and has sole voting and investment control over the shares owned by Nextech Crossover LP and may be deemed to own beneficially the shares held by Nextech Crossover LP. Nextech Crossover GP owns no securities of the Issuer directly. Charoub, Constantinides and Sgobbo are members of the board of managers of Nextech Crossover GP and share voting and dispositive power over the shares held by Nextech Crossover LP, and may be deemed to own beneficially the shares held by Nextech Crossover LP. Charoub, Constantinides and Sgobbo own no securities of the Issuer directly.

 

(2)     The percent of class was calculated based on the sum of (i) 88,467,269 shares of Common Stock outstanding as of August 2, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2023, and (ii) 13,196,671 shares of Common Stock issued in the private placement of equity securities by the Issuer that closed on August 11, 2023.

 

Item 5. Ownership of Five Percent or Less of a Class
   
  If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ¨
 
Item 6. Ownership of More than Five Percent on Behalf of Another Person
   
  Not applicable
 
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
   
  Not applicable
 
Item 8. Identification and Classification of Members of the Group
   
  Not applicable
 
Item 9. Notice of Dissolution of Group
   
  Not applicable
 
Item 10. Certification
   
  By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

 

8

 

 

Signature

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: August 21, 2023  
   
Nextech Crossover I SCSp  
   
By: Nextech Crossover I GP S.à r.l.  
its General Partner  
   
By: /s/ Ian Charoub  
  Name: Ian Charoub  
  Title: Manager  
   
By: /s/ Costas Constantinides  
  Name: Costas Constantinides  
  Title: Manager  
   
Nextech Crossover I GP S.à r.l.  
   
By: /s/ Ian Charoub  
    Name: Ian Charoub  
    Title: Manager  
   
By: /s/ Costas Constantinides  
    Name: Costas Constantinides  
    Title: Manager  
   
/s/ Ian Charoub  
Ian Charoub  
   
/s/ Costas Constantinides  
Costas Constantinides  
   
/s/ Rocco Sgobbo  
Rocco Sgobbo  

 

  ATTENTION  
Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

 

9

 

 

Exhibit(s):

 

AJoint Filing Agreement

 

10

 

 

EXHIBIT A

 

JOINT FILING AGREEMENT

 

We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of Tango Therapeutics, Inc. is filed on behalf of each of us.

 

Dated: August 21, 2023  
   
Nextech Crossover I SCSp  
   
By: Nextech Crossover I GP S.à r.l.  
its   General Partner  
   
By: /s/ Ian Charoub  
  Name: Ian Charoub  
  Title: Manager  
   
By: /s/ Costas Constantinides  
  Name: Costas Constantinides  
  Title: Manager  
   
Nextech Crossover I GP S.à r.l.  
   
By: /s/ Ian Charoub  
    Name: Ian Charoub  
    Title: Manager  
   
By: /s/ Costas Constantinides  
    Name: Costas Constantinides  
    Title: Manager  
   
/s/ Ian Charoub  
Ian Charoub  
   
/s/ Costas Constantinides  
Costas Constantinides  
   
/s/ Rocco Sgobbo  
Rocco Sgobbo  

 

11

 

Tango Therapeutics (NASDAQ:TNGX)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Tango Therapeutics Charts.
Tango Therapeutics (NASDAQ:TNGX)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Tango Therapeutics Charts.